Schizophrenia Treatments
Schizophrenia is a brain disorder that results in hallucinations, paranoid delusions, confused or disordered thinking and/or speech, difficulty concentrating and functioning, and other negative symptoms. It is diagnosed according to criteria described by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V, 2013): the individual should show signs of hallucinations, delusions or disorganized speech in a continuous manner for at least 6 months, with 1 at least one month of active symptoms occurring that negatively impacts the person’s ability to work or socialize consistently. The World Health Organization (2017) states that roughly 21 million people throughout the world suffer from schizophrenia. Schizophrenia is a treatable disease, however, and as Saks (2009) shows, an individual can lead a normal life while having schizophrenia because there are a number of treatments available to help control the symptoms.
Treatments
Treatments available for individuals who suffer from schizophrenia typically include a combination of pharmacological approaches and therapeutic approaches. Pharmacological treatments include antipsychotic mood stabilizers called neuroleptics. Therapeutic interventions include a wide range of methods, such as support group therapy or psychosocial therapy. Dietary supplements like Glycine are also utilized along with mood stabilizers or anti-depressants. In extreme cases, electroconvulsive therapy has been used to stabilize individuals who suffer from schizophrenia (Kates, Dequardo & Tandon, 1999).
Antipsychotics or neuroleptics are commonly used to treat schizophrenia and typically result in a reduction of the positive symptoms of the disease. There are a variety of drug choices available as Leucht, Cipriani, Spineli et al. (2013) showed in their comparative study of 15 antipsychotic drugs used to treat schizophrenia. Their meta-analysis of 212 suitable trials including data from over 43,000 patients showed that all fifteen of the drugs “were significantly more effective than placebo” (Leucht et al., 2013, p. 951). Drugs can differ in terms of the side effects they cause, so finding the right drug for the patient can sometimes be a process of trial and error, as a lot of the pharmacological success of this treatment depends on how the individual responds to the drug. Nonetheless, neuroleptics are viewed as an important treatment method in the stabilization of the subject.
Other psychotropic drugs are often prescribed and polypharmacy is common method of treatment, as Zink, Englisch and Meyer-Lindenberg (2010) show in their review of treatment options for schizophrenic patients. The purpose of polypharmacy is to address issues of cognitive disturbance, comorbidity, obsessive-compulsive syndromes, and other side effects that stem from antipsychotic treatment. As their study shows, “the add-on of lithium and mood stabilizers lacks compelling evidence, but might be beneficial for specific subgroups” and “for treatment-resistant cognitive symptoms, antipsychotic medication should be combined with cognitive remediation, as no pharmacological add-on strategy has gained convincing evidence so far” (Zink et al., 2010, p. 103).
In the early stages of the treatment, the patient may require to be hospitalized and even restrained to prevent self-injury or injury to others. As Saks (2009) has shown, this type of treatment, while necessary in the short-term, can cause long-term negative consequences and prevent the patient from wanting to seek treatment later on as the memories of being restrained against one’s will can be very traumatic for the patient and cause the patient to want to avoid hospitals and doctors. Saks (2009) recommends that patients be consulted once stabilized regarding how they would like to be treated in the future should they ever present themselves in a condition where they are unable to function or respond clearly to questions or commands. By giving patients a say when they are stable as to whether they would like to be forcefully restrained as a precautionary measure in the future, schizophrenic individuals can feel more confident about having their rights and personhood respected. This can be an important point to remember when it comes to treating individuals suffering from this disease.
Therapies that are often used in treating schizophrenic patients include cognitive behavioral therapy (CBT), support group therapy, psychoanalysis, and psychosocial therapy. Studies by Turkington, Kingdon and Turner (2002) show that CBT is an effective way to help stabilize schizophrenic patients in a brief amount of time and can be given safely by psychiatric nurses to help improve the lives of schizophrenic patients. CBT works effectively because...
References
American Psychiatric Association. (2004). Treating schizophrenia. Retrieved from http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia-guide.pdf
DSM-V. (2013). American Psychiatric Association. Retrieved from https://www.psychiatry.org/psychiatrists/practice/dsm
Kales, H. C., Dequardo, J. R., & Tandon, R. (1999). Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 23(3), 547-556.
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R.R., Geddes, J.R. and Kissling, W. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.
Saks, E. (2009). Diary of a High-Functioning Person with Schizophrenia. Scientific American. Retrieved from http://www.scientificamerican.com/article/diary-of-a-high-function/.
Turkington, D., Kingdon, D., & Turner, T. (2002). Effectiveness of a brief cognitive—behavioural therapy intervention in the treatment of schizophrenia. The British Journal of Psychiatry, 180(6), 523-527.
World Health Organization. (2017). Schizophrenia. Retrieved from http://www.who.int/mental_health/management/schizophrenia/en/
Zink, M., Englisch, S., & Meyer-Lindenberg, A. (2010). Polypharmacy in schizophrenia. Current Opinion in Psychiatry, 23(2), 103-111.
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now